TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter...(et for acute and prophylactic migraine t...),Health

is a member of the American Headache Society, The International

Headache Society and The National Headache Foundation. Dr. Goldstein

is a Board Certified Neurologist, a Fellow of the American Academy of

Neurology, and has special qualification for the treatment of headache

from the National Headache Foundation. He has received many industry

awards, published articles in industry journals and served on advisory

boards related to the development of a wide range of headache

therapies.

-- Alan J. Tuchman, M.D., Clinical Professor of Neurology and Pharmacology at New York Medical College, Principal of a neuroscience-focused consulting firm and a board-certified neurologist

Dr. Tuchman will present information about glutamate receptors in the

spinal cord as a target for muscle spasticity. He has served as Vice

Chairman of the Department of Neurology at New York Medical College as

well as Vice Dean of Clinical Affairs, which involved the development

and management of clinical care and medical education policy for 29

affiliated hospitals. In addition, he was President of the Epilepsy

Society of Southern New York. Dr. Tuchman is a frequent speaker about

neuroscience topics at academic meetings.

"There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."

TorreyPines Therapeutics' lead compound, tezampanel is the first AMPA/kainate-type glutamate receptor antagonist
'/>"/>